These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

533 related articles for article (PubMed ID: 24464532)

  • 21. Development of
    Potemkin R; Strauch B; Kuwert T; Prante O; Maschauer S
    Mol Pharm; 2020 Mar; 17(3):933-943. PubMed ID: 32011889
    [TBL] [Abstract][Full Text] [Related]  

  • 22. PSMA, EpCAM, VEGF and GRPR as imaging targets in locally recurrent prostate cancer after radiotherapy.
    Rybalov M; Ananias HJ; Hoving HD; van der Poel HG; Rosati S; de Jong IJ
    Int J Mol Sci; 2014 Apr; 15(4):6046-61. PubMed ID: 24727373
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Will GRPR Compete with PSMA as a Target in Prostate Cancer?
    Iagaru A
    J Nucl Med; 2017 Dec; 58(12):1883-1884. PubMed ID: 28970333
    [No Abstract]   [Full Text] [Related]  

  • 24. Development of Heterobivalent Theranostic Probes Having High Affinity/Selectivity for the GRPR/PSMA.
    Bandari RP; Carmack TL; Malhotra A; Watkinson L; Fergason Cantrell EA; Lewis MR; Smith CJ
    J Med Chem; 2021 Feb; 64(4):2151-2166. PubMed ID: 33534560
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Current use of PSMA-PET in prostate cancer management.
    Maurer T; Eiber M; Schwaiger M; Gschwend JE
    Nat Rev Urol; 2016 Apr; 13(4):226-35. PubMed ID: 26902337
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dual-Modality Imaging of Prostate Cancer with a Fluorescent and Radiogallium-Labeled Gastrin-Releasing Peptide Receptor Antagonist.
    Zhang H; Desai P; Koike Y; Houghton J; Carlin S; Tandon N; Touijer K; Weber WA
    J Nucl Med; 2017 Jan; 58(1):29-35. PubMed ID: 27516447
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Theranostic Perspectives in Prostate Cancer with the Gastrin-Releasing Peptide Receptor Antagonist NeoBOMB1: Preclinical and First Clinical Results.
    Nock BA; Kaloudi A; Lymperis E; Giarika A; Kulkarni HR; Klette I; Singh A; Krenning EP; de Jong M; Maina T; Baum RP
    J Nucl Med; 2017 Jan; 58(1):75-80. PubMed ID: 27493272
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bispecific GRPR-Antagonistic Anti-PSMA/GRPR Heterodimer for PET and SPECT Diagnostic Imaging of Prostate Cancer.
    Mitran B; Varasteh Z; Abouzayed A; Rinne SS; Puuvuori E; De Rosa M; Larhed M; Tolmachev V; Orlova A; Rosenström U
    Cancers (Basel); 2019 Sep; 11(9):. PubMed ID: 31540122
    [TBL] [Abstract][Full Text] [Related]  

  • 29. 18F-labeled bombesin analog for specific and effective targeting of prostate tumors expressing gastrin-releasing peptide receptors.
    Honer M; Mu L; Stellfeld T; Graham K; Martic M; Fischer CR; Lehmann L; Schubiger PA; Ametamey SM; Dinkelborg L; Srinivasan A; Borkowski S
    J Nucl Med; 2011 Feb; 52(2):270-8. PubMed ID: 21233180
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Expression of the gastrin-releasing peptide receptor, the prostate stem cell antigen and the prostate-specific membrane antigen in lymph node and bone metastases of prostate cancer.
    Ananias HJ; van den Heuvel MC; Helfrich W; de Jong IJ
    Prostate; 2009 Jul; 69(10):1101-8. PubMed ID: 19343734
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Preclinical Evaluation and First Patient Application of 99mTc-PSMA-I&S for SPECT Imaging and Radioguided Surgery in Prostate Cancer.
    Robu S; Schottelius M; Eiber M; Maurer T; Gschwend J; Schwaiger M; Wester HJ
    J Nucl Med; 2017 Feb; 58(2):235-242. PubMed ID: 27635024
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Enhancing Treatment Efficacy of
    Kuo HT; Merkens H; Zhang Z; Uribe CF; Lau J; Zhang C; Colpo N; Lin KS; Bénard F
    Mol Pharm; 2018 Nov; 15(11):5183-5191. PubMed ID: 30251544
    [TBL] [Abstract][Full Text] [Related]  

  • 33. microPET and autoradiographic imaging of GRP receptor expression with 64Cu-DOTA-[Lys3]bombesin in human prostate adenocarcinoma xenografts.
    Chen X; Park R; Hou Y; Tohme M; Shahinian AH; Bading JR; Conti PS
    J Nucl Med; 2004 Aug; 45(8):1390-7. PubMed ID: 15299066
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In vitro and in vivo evaluation of the bifunctional chelator NODIA-Me in combination with a prostate-specific membrane antigen targeting vector.
    Läppchen T; Kiefer Y; Holland JP; Bartholomä MD
    Nucl Med Biol; 2018 May; 60():45-54. PubMed ID: 29571066
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Novel multifunctional
    Kwon YD; Lee JY; La MT; Lee SJ; Lee SH; Park JH; Kim HK
    Eur J Med Chem; 2020 Mar; 189():112099. PubMed ID: 32014792
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Synthesis and Preclinical Characterization of the PSMA-Targeted Hybrid Tracer PSMA-I&F for Nuclear and Fluorescence Imaging of Prostate Cancer.
    Schottelius M; Wurzer A; Wissmiller K; Beck R; Koch M; Gorpas D; Notni J; Buckle T; van Oosterom MN; Steiger K; Ntziachristos V; Schwaiger M; van Leeuwen FWB; Wester HJ
    J Nucl Med; 2019 Jan; 60(1):71-78. PubMed ID: 30237214
    [TBL] [Abstract][Full Text] [Related]  

  • 37. 99mTc-labeled small-molecule inhibitors of prostate-specific membrane antigen for molecular imaging of prostate cancer.
    Hillier SM; Maresca KP; Lu G; Merkin RD; Marquis JC; Zimmerman CN; Eckelman WC; Joyal JL; Babich JW
    J Nucl Med; 2013 Aug; 54(8):1369-76. PubMed ID: 23733925
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Full preclinical validation of the 123I-labeled anti-PSMA antibody fragment ScFvD2B for prostate cancer imaging.
    Frigerio B; Franssen G; Luison E; Satta A; Seregni E; Colombatti M; Fracasso G; Valdagni R; Mezzanzanica D; Boerman O; Canevari S; Figini M
    Oncotarget; 2017 Feb; 8(7):10919-10930. PubMed ID: 28051996
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Albumin-Binding PSMA Ligands: Optimization of the Tissue Distribution Profile.
    Benešová M; Umbricht CA; Schibli R; Müller C
    Mol Pharm; 2018 Mar; 15(3):934-946. PubMed ID: 29400475
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Radiolabeled enzyme inhibitors and binding agents targeting PSMA: Effective theranostic tools for imaging and therapy of prostate cancer.
    Pillai MRA; Nanabala R; Joy A; Sasikumar A; Russ Knapp FF
    Nucl Med Biol; 2016 Nov; 43(11):692-720. PubMed ID: 27589333
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.